ASCEnD
ASCEnD is a clinical and cost-effectiveness study of aripiprazole combined with sertraline for patients with bipolar depression. It is running in 10 sites across the UK and will be starting recruitment in June 2023.
ASCEnD is a clinical and cost-effectiveness study of aripiprazole combined with sertraline for patients with bipolar depression. It is running in 10 sites across the UK and will be starting recruitment in June 2023.